Total
0
Shares
Source: Nextleaf Solutions
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Nextleaf Solutions (OILS) has been granted a U.S. patent for its novel process of acetylating Cannabigerol (CBG)
  • The company’s latest U.S. patent is for the process of modifying the CBG found in cannabis distillate into a prodrug referred to as CBG-O-Acetate
  • Nextleaf believes that the CBG-derived prodrug produced under its patented process may hold significant potential as a therapeutic product
  • Nextleaf is a federally regulated producer of cannabis oil that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids
  • Nextleaf Solutions (OILS) is up 15.79 per cent, trading at $0.22 per share

Nextleaf Solutions (OILS) has been granted a U.S. patent for its novel process of acetylating Cannabigerol (CBG).

Acetylation is an organic esterification reaction that often uses acetic acid. Nextleaf has already been granted U.S. and Canadian patents for the acetylation of both CBD and THC and the subsequent refinement of CBD-O-Acetate and THC-O-Acetate.

Its latest U.S. patent is for a proprietary production process of modifying the CBG found in cannabis distillate into a prodrug referred to as CBG-O-Acetate.

Paul Pedersen, Nextleaf co-founder, and CEO commented on the new patent.

“We are thrilled to enhance our U.S. patent portfolio with this novel production process,” he said, “that along with our Health Canada licenses, allows Nextleaf to develop and produce truly differentiated cannabinoid-based products through our Specialty Molecules Division.”

Nextleaf believes that the CBG-derived prodrug produced under its patented process may hold significant potential as a therapeutic product.

Research suggests that CBG may be effective in the treatment of inflammation, pain, and nausea, and some peer-reviewed research suggests that CBG in higher doses could be used to treat conditions like Crohn’s disease and cancer.

“CBG is often referred to as the mother cannabinoid as so many other cannabinoids can be derived from its acidic form,” said patent author and Nextleaf Chief Technology Officer Ryan Ko. “This issuance provides further validation for our specialty molecules development roadmap.”

Nextleaf is a federally regulated producer of cannabis oil that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids.

Nextleaf Solutions (OILS) is up 15.79 per cent, trading at $0.22 as of 2:47 pm ET.

More From The Market Herald
True Leaf Brands - CEO, Darcy Bomford (left)

" True Leaf (CSE:MJ) secures additional debt funding

True Leaf Brands (MJ) has received new debt funding for its Monashee Gateway Business Park project and cannabis processing facility.

" Ayurcann Holdings (CSE:AYUR) enters into a patient-referral agreement with The Herb Clinic

Ayurcann Holdings (AYUR) has entered into a patient-referral agreement with The Herb Clinic.

" InterCure (TSX:INCR.U) reports record Q3 revenue

InterCure (INCR.U) has announced preliminary unaudited revenue of C$24 million for the third quarter of 2021.

" Nutritional High’s (CSE:EAT) California businesses aided by new ordinance vote

Nutritional High’s (EAT) OutCo acquisition will benefit from a recent vote by the San Diego County Board of Supervisors.